Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; Inhibition rate of ~90% observed in GP2D human colorectal cancer cells; Company to conduct additional preclinical study focused on lung cancer cell lines GRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a... Read More

Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional KRAS-driven tumor types with treatment markets estimated at over $30 Billion Dollars a year GRAND CAYMAN, Cayman Islands, May 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion” or the “Company”), a... Read More

Significant advancements in preclinical pipeline for SIL204, with groundbreaking data demonstrating efficacy against both primary tumors and metastases in orthotopic models; strengthened financial position with over $9 million gross funds raised in Q1 2025 GRAND CAYMAN, Cayman Islands, May 13, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech company... Read More

Grand Cayman, Cayman Islands, April 23, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“ Silexion ” or the “ Company ”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a strategic collaboration with Catalent, a global leader in advanced delivery technologies, clinical development, and manufacturing solutions for therapeutics.... Read More

Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced an expanded development plan for its next-generation siRNA candidate, SIL204. This strategy integrates systemic administration to target metastatic progression with... Read More

Grand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company’s management will be presenting at the upcoming Cancer Advocacy... Read More

Grand Cayman, Cayman Islands, March 18, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. Ilan Hadar, Chairman and CEO of Silexion,... Read More

Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced positive data from orthotopic pancreatic cancer models demonstrating that subcutaneously administered SIL204 effectively reduces both primary tumor growth and... Read More

Grand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This milestone represents the first systematic evaluation of SIL-204... Read More

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,221,523 of the Company’s ordinary shares originally issued in... Read More

Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced promising new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings contribute to validating systemic administration as an effective delivery approach,... Read More

Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,703,703 of the Company’s ordinary shares (or ordinary share equivalents) and warrants to purchase up to 3,703,703 ordinary shares at a... Read More